Zhi Tong Cai Jing·2026-01-29 09:40Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-7535, a novel oral small molecule GLP-1 receptor agonist, which shows promise in treating chronic kidney disease and obesity-related conditions [1] Group 1: Product Development - HRS-7535 is designed to activate GLP-1 receptors, promoting insulin secretion and reducing glucagon secretion while also suppressing gastric emptying [1] - The drug has shown significant improvement in preclinical models of chronic kidney disease (CKD) [1] - The total research and development investment for HRS-7535 has reached approximately 36.94 million yuan (unaudited) [1] Group 2: Market Context - There are currently no oral small molecule GLP-1 receptor agonists available in the global market [1]